Literature DB >> 22898238

Evaluation of the willingness-to-pay for cancer treatment in Korean metastatic breast cancer patients: a multicenter, cross-sectional study.

Do-Youn Oh1, Bruce Crawford, Sung-Bae Kim, Hyun-Cheol Chung, Jeffrey McDonald, Sang Yoon Lee, Su-Kyoung Ko, Jungsil Ro.   

Abstract

AIMS: To evaluate the inherent value of breast cancer therapy a willingness-to-pay (WTP) study was conducted in Korean patients with metastatic breast cancer.
METHODS: Patients were prospectively enrolled from four study centers and completed quality of life questionnaires to reflect their status pre-cancer and their current health status. Clinical and socioeconomic data were collected to characterize the population and utilize during modeling. Patients' WTP for breast cancer treatment was assessed using an open-ended question following three rounds of bidding to better hone in on their maximal WTP, starting with one of three randomly assigned start bids. Predictors of patient WTP was evaluated using linear regression models. Associations between WTP and other parameters were evaluated with correlations.
RESULTS: Korean metastatic breast cancer patients were WTP an average of KRW 8 696 329 (US$7555) per month to return to their pre-cancer health state, with those who were recently diagnosed as WTP the most (KRW 12 955 000 [$11 254]). WTP was closely associated with the patient's education level, income, personal financial difficulties, Eastern Cooperative Oncology Group performance status, and their experience of arm symptoms.
CONCLUSION: The results suggest that patients are WTP significant amounts per month for treatment. Breast cancer patients are heavily burdened physically, mentally and financially, and the present study indicated this significant financial burden by disclosing its relationship with WTP. Providing a better understanding of the inherent value of treatment will allow Koreans to better evaluate treatment in the coming era of personalized medicine.
© 2012 Wiley Publishing Asia Pty Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22898238     DOI: 10.1111/j.1743-7563.2012.01546.x

Source DB:  PubMed          Journal:  Asia Pac J Clin Oncol        ISSN: 1743-7555            Impact factor:   2.601


  5 in total

Review 1.  Stated and Revealed Preferences for Funding New High-Cost Cancer Drugs: A Critical Review of the Evidence from Patients, the Public and Payers.

Authors:  Tatjana E MacLeod; Anthony H Harris; Ajay Mahal
Journal:  Patient       Date:  2016-06       Impact factor: 3.883

2.  Willingness-to-pay for cancer treatment and outcome: a systematic review.

Authors:  Alene Sze Jing Yong; Yi Heng Lim; Mark Wing Loong Cheong; Ednin Hamzah; Siew Li Teoh
Journal:  Eur J Health Econ       Date:  2021-12-02

3.  Willingness to pay for a cure of low-risk melanoma patients in Germany.

Authors:  Matthias Augustin; Christine Blome; Andrea Forschner; Ralf Gutzmer; Axel Hauschild; Lucie Heinzerling; Elisabeth Livingstone; Carmen Loquai; Dirk Schadendorf; Jochen Utikal; Tobias Wagner; Sophia Wilden; Katharina C Kähler
Journal:  PLoS One       Date:  2018-05-24       Impact factor: 3.240

4.  Disparities in healthcare expenditures according to economic status in cancer patients undergoing end-of-life care.

Authors:  Kyu-Tae Han; Woorim Kim; Seungju Kim
Journal:  BMC Cancer       Date:  2022-03-22       Impact factor: 4.430

5.  A Systematic Literature Review of Health Utility Values in Breast Cancer.

Authors:  Manraj N Kaur; Jiajun Yan; Anne F Klassen; Justin P David; Dilshan Pieris; Manraj Sharma; Louise Bordeleau; Feng Xie
Journal:  Med Decis Making       Date:  2022-01-18       Impact factor: 2.749

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.